Common Stock, par value $0.00001 per share
- Symbol
- ZYME
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 9.01 · 8-K/A
Zymeworks Inc.
ZYMENASDAQEQUITYCurrent
Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial statements of businesses or funds acquired. The (i) audited financial statements of Theravance and accompanying notes related thereto as of and for the years ended December 31, 2025 and December 31, 2024 are filed herewith as Exhibit 99.1 and are incorporated by reference herein and the (ii) unaudited financial statements of Theravance for…
Company context
Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
Current securities
Registered securities in this filing
Zymeworks Inc. · 8-K/A · Filed 2026-11-09
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(a) Financial statements of businesses or funds acquired.
The (i) audited financial statements of Theravance and accompanying notes related thereto as of and for the years ended December 31, 2025 and December 31, 2024 are filed herewith as Exhibit 99.1 and are incorporated by reference herein and the (ii) unaudited financial statements of Theravance for the six month periods ended June 30, 2026 and 2025 are filed herewith as Exhibit 99.2 and are incorporated by reference herein (together, the “Target Financial Statements”).
(b) Pro forma financial information.
The unaudited pro forma condensed combined financial information for the fiscal year ended December 31, 2025 and the nine months ended September 30, 2026 and the accompanying notes related thereto are filed herewith as Exhibit 99.3 and are incorporated by reference herein.
Exhibit Description
No.
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
23.1 Consent of Ernst & Young LLP
99.1 Audited financial statements of Theravance Biopharma, Inc. and accompanying notes related thereto as of and for the years ended December 31, 2025 and December 31, 2024 (incorporated by reference to Part IV, Item 15(a) of the Annual Report on Form 10-K of Theravance Biopharma, Inc. (File No. 001-36033), filed on March 23, 2026).
99.2 Unaudited interim financial statements of Theravance Biopharma, Inc. and accompanying notes related thereto as of June 30, 2026 and December 31, 2025, and for the six month periods ended June 30, 2026 and 2025 (incorporated by reference to Part I, Item 1 of the Quarterly Report on Form 10-Q of Theravance Biopharma, Inc. (File No. 001-36033), filed on August 11, 2026).
99.3 Unaudited pro forma condensed combined financial information of Zymeworks Inc. and accompanying notes related thereto for the fiscal year ended December 31, 2025 and for the nine months ended September 30, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).